Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
-
Wondering if DiaSorin at €61.66 still reflects its true worth, or if the market is missing something you can spot before others do?
-
The share price has seen a 5.8% gain over the last 7 days, alongside declines of 10.3% over the last 30 days, 9.9% year to date, and 33.0% over the past year, so recent moves may be changing how investors think about both risk and opportunity here.
-
Recent coverage around DiaSorin has focused on its position in the Medical Equipment space and how sentiment has shifted after a multi year share price decline. That context helps explain why shorter term gains are attracting fresh attention, even while longer term returns remain under pressure.
-
On Simply Wall St's valuation checks, DiaSorin scores a 4 out of 6. This raises useful questions about what each method is seeing in the stock and hints at an even more complete way to think about valuation that will be covered later in this article.
Find out why DiaSorin's -33.0% return over the last year is lagging behind its peers.
Approach 1: DiaSorin Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today's value. For DiaSorin, the model used here is a 2 Stage Free Cash Flow to Equity approach.
DiaSorin's latest twelve month free cash flow is about €225.6 million. Analyst inputs and subsequent projections, which extend out to 2035, indicate free cash flows in the range of roughly €208.6 million in 2026 and €330.8 million in 2035, with €256 million projected for 2028. Simply Wall St extrapolates beyond the analyst horizon to complete the ten year path.
After discounting each of these projected cash flows back to today, the model arrives at an estimated intrinsic value of €62.63 per share. Against the current share price of €61.66, that indicates DiaSorin trades at roughly a 1.5% discount, which is a very small gap.
On this cash flow view, DiaSorin appears close to fairly priced with only a slight hint of upside.
Result: ABOUT RIGHT
DiaSorin is fairly valued according to our Discounted Cash Flow (DCF) , but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Approach 2: DiaSorin Price vs Earnings
P/E is a common way to value profitable companies because it links what you pay for each share directly to the earnings that support that share. In general, higher growth expectations or lower perceived risk tend to justify a higher P/E, while slower growth or higher risk usually point to a lower, more conservative multiple.
DiaSorin currently trades on a P/E of 22.17x. This sits below the Medical Equipment industry average of 25.02x and the peer group average of 24.01x, which suggests the market is pricing the shares at a discount to many comparable names.
Simply Wall St's Fair Ratio for DiaSorin is 24.27x. This is a proprietary estimate of what a "normal" P/E might be, based on factors like earnings growth, profit margins, industry, market cap and company specific risks, rather than a simple comparison with broad peers. Because it adjusts for these fundamentals, the Fair Ratio aims to give a more tailored anchor than raw industry or peer averages.
With the current P/E of 22.17x sitting below the Fair Ratio of 24.27x, DiaSorin screens as undervalued on this earnings based lens.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 96 top founder-led companies .
Upgrade Your Decision Making: Choose your DiaSorin Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple tool on Simply Wall St's Community page that lets you attach a clear story about DiaSorin to specific forecasts for revenue, earnings, margins and a Fair Value, then automatically compare that Fair Value with the current price to help you decide whether the stock looks attractive or stretched right now.
Each Narrative connects what you believe about DiaSorin, such as slower earnings conversion and margin strain pointing to a Fair Value of €58 and a bearish price target around €68, or stronger execution and hospital expansion supporting a higher Fair Value of €105 and a bullish price target of €122, to a full set of numbers that are continuously refreshed when new news, earnings or analyst estimates appear, so you can see in real time how different viewpoints translate into different fair values and decide which story best matches your own expectations before making any move.
For DiaSorin however we will make it really easy for you with previews of two leading DiaSorin Narratives:
🐂 DiaSorin Bull Case
Fair value in this bullish consensus style narrative is about €81.39 per share.
At the current price of €61.66, that is roughly 24.3% below this fair value estimate using the formula ((81.39 - 61.66) / 81.39).
Analysts in this narrative framework are using a revenue growth assumption of about 7.0% a year.
-
Expansion in North America and emerging markets, plus new specialty diagnostics, is used to support expectations for sustained revenue and margin improvement.
-
Manufacturing consolidation and automation are expected to keep cost pressure in check while supporting profitability.
-
Partnership driven assay launches and a refreshed test menu are central to the view that DiaSorin can keep pricing power and defend returns.
🐻 DiaSorin Bear Case
Fair value in this more cautious bearish narrative is set at about €58.00 per share.
With the current price at €61.66, that sits around 6.3% above this fair value estimate, using ((61.66 - 58.00) / 58.00).
This narrative is built around a revenue growth assumption of roughly 6.2% a year.
-
Global cost controls, rising healthcare procurement pressure, and a shift toward point of care testing are viewed as headwinds for pricing and demand.
-
Greater regulatory and compliance demands, along with currency swings, are seen as adding earnings volatility and weighing on margins.
-
The analysts behind this view see a lower earnings multiple and a fair value of €58.00 as more appropriate if revenue growth and margin gains track closer to the bearish assumptions.
Whichever story feels closer to how you see DiaSorin, the most useful step now is to test your own expectations against these numbers and see where you agree or disagree before taking any action.
Do you think there's more to the story for DiaSorin? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include DIA.MI .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
